Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5.F35-hGCC-PADRE Vaccine in Gastrointestinal Adenocarcinomas
NCT04111172Phase 2Suspended
- Sponsor
- Thomas Jefferson University
- Start
- Nov 2020
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Ad5.F35-GUCY2C-PADRE in pancreatic ductal adenocarcinoma (PDAC), colorectal adenocarcinoma, gastric adenocarcinoma, esophageal adenocarcinoma (EAC), Small intestinal adenocarcinoma (SBA), sponsored by Thomas Jefferson University. Started Nov 2020; status: suspended.
02
Drugs
Ad5.F35-GUCY2C-PADRE
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)colorectal adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)Small intestinal adenocarcinoma (SBA)
Beyond the preview
Go deeper on NCT04111172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04111172.